KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Non Operating Income (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Other Non Operating Income for 14 consecutive years, with $201.2 million as the latest value for Q1 2026.

  • For Q1 2026, Other Non Operating Income fell 37.52% year-over-year to $201.2 million; the TTM value through Mar 2026 reached $1.6 billion, up 31.21%, while the annual FY2025 figure was $1.7 billion, 100.92% up from the prior year.
  • Other Non Operating Income hit $201.2 million in Q1 2026 for Regeneron Pharmaceuticals, up from $176.0 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $755.8 million in Q3 2025 and bottomed at -$183.8 million in Q1 2022.
  • Average Other Non Operating Income over 5 years is $185.1 million, with a median of $193.0 million recorded in 2023.
  • On a YoY basis, Other Non Operating Income climbed as much as 1937.8% in 2022 and fell as far as 218.66% in 2022.
  • Regeneron Pharmaceuticals' Other Non Operating Income stood at $195.3 million in 2022, then decreased by 1.18% to $193.0 million in 2023, then plummeted by 111.19% to -$21.6 million in 2024, then skyrocketed by 914.81% to $176.0 million in 2025, then grew by 14.32% to $201.2 million in 2026.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at $201.2 million, $176.0 million, and $755.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.